Editing Serotonin (section)

===Appetite suppressants===
Some [[serotonin releasing agent]]s, [[serotonin reuptake inhibitor]]s, and/or serotonin [[5-HT2C receptor|5-HT<sub>2C</sub> receptor]] [[agonist]]s, such as [[fenfluramine]], [[dexfenfluramine]], [[chlorphentermine]], [[sibutramine]], and [[lorcaserin]], have been approved and used as [[appetite suppressant]]s for purposes of [[weight loss]] in the treatment of [[overweightness]] or [[obesity]].<ref name="HalfordHarroldBoyland2007">{{cite journal | vauthors = Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE | title = Serotonergic drugs : effects on appetite expression and use for the treatment of obesity | journal = Drugs | volume = 67 | issue = 1 | pages = 27–55 | date = 2007 | pmid = 17209663 | doi = 10.2165/00003495-200767010-00004 | url = }}</ref><ref name="HurrenBerlie2011">{{cite journal | vauthors = Hurren KM, Berlie HD | title = Lorcaserin: an investigational serotonin 2C agonist for weight loss | journal = Am J Health Syst Pharm | volume = 68 | issue = 21 | pages = 2029–2037 | date = November 2011 | pmid = 22011982 | doi = 10.2146/ajhp100638 | url = }}</ref><ref name="HalfordBoylandLawton2011">{{cite journal | vauthors = Halford JC, Boyland EJ, Lawton CL, Blundell JE, Harrold JA | title = Serotonergic anti-obesity agents: past experience and future prospects | journal = Drugs | volume = 71 | issue = 17 | pages = 2247–2255 | date = December 2011 | pmid = 22085383 | doi = 10.2165/11596680-000000000-00000 | url = }}</ref><ref name="HalfordHarrold2012">{{cite book | vauthors = Halford JC, Harrold JA | chapter = 5-HT2C Receptor Agonists and the Control of Appetite | title = Handbook of Experimental Pharmacology | volume = 209| issue = 209 | pages = 349–356 | date = 2012 | pmid = 22249823 | doi = 10.1007/978-3-642-24716-3_16 | isbn = 978-3-642-24715-6 | chapter-url = }}</ref><ref name="PrzegalińskiWitekWydra2023">{{cite journal | vauthors = Przegaliński E, Witek K, Wydra K, Kotlińska JH, Filip M | title = 5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators | journal = Nutrients | volume = 15 | issue = 6 | date = March 2023 | page = 1449 | pmid = 36986191 | pmc = 10058696 | doi = 10.3390/nu15061449 | doi-access = free | url = }}</ref> Several of the preceding agents have been [[withdrawn drug|withdrawn from the market]] due to [[toxicity]], such as [[cardiac fibrosis]] or [[pulmonary hypertension]].<ref name="PrzegalińskiWitekWydra2023" />